{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-+Breast+Cancer&page=18",
    "query": {
      "condition": "HER2- Breast Cancer",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 1358,
    "total_pages": 136,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-+Breast+Cancer&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2-+Breast+Cancer&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T11:27:03.629Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01846091",
      "title": "Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Estrogen Receptor Negative",
        "Estrogen Receptor Positive",
        "Head and Neck Squamous Cell Carcinoma",
        "HER2/Neu Negative",
        "HER2/Neu Positive",
        "Invasive Breast Carcinoma",
        "Progesterone Receptor Negative",
        "Progesterone Receptor Positive",
        "Recurrent Head and Neck Carcinoma",
        "Stage IV Breast Cancer",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2013-04-09",
      "completion_date": "2019-11-26",
      "has_results": false,
      "last_update_posted_date": "2023-02-14",
      "last_synced_at": "2026-10-26T11:27:03.629Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01846091"
    },
    {
      "nct_id": "NCT02384746",
      "title": "Phase I Study of the Combination of MLN9708 and Fulvestrant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "MLN9708",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2015-06-02",
      "completion_date": "2018-06-10",
      "has_results": false,
      "last_update_posted_date": "2019-04-29",
      "last_synced_at": "2026-10-26T11:27:03.629Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02384746"
    },
    {
      "nct_id": "NCT05501769",
      "title": "ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ARV-471 in combination with Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arvinas Estrogen Receptor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2022-09-08",
      "completion_date": "2025-08-25",
      "has_results": false,
      "last_update_posted_date": "2025-09-26",
      "last_synced_at": "2026-10-26T11:27:03.629Z",
      "location_count": 6,
      "location_summary": "San Diego, California • Santa Monica, California • Washington D.C., District of Columbia + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05501769"
    },
    {
      "nct_id": "NCT06465368",
      "title": "A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "PF-07220060",
          "type": "DRUG"
        },
        {
          "name": "letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 121,
      "start_date": "2024-07-11",
      "completion_date": "2025-07-10",
      "has_results": true,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-10-26T11:27:03.629Z",
      "location_count": 10,
      "location_summary": "Barrington, Illinois • Crystal Lake, Illinois • Park Ridge, Illinois + 2 more",
      "locations": [
        {
          "city": "Barrington",
          "state": "Illinois"
        },
        {
          "city": "Crystal Lake",
          "state": "Illinois"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06465368"
    },
    {
      "nct_id": "NCT02792725",
      "title": "Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-10-31",
      "last_synced_at": "2026-10-26T11:27:03.629Z",
      "location_count": 10,
      "location_summary": "Monterey, California • Santa Monica, California • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02792725"
    },
    {
      "nct_id": "NCT05736367",
      "title": "Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "U-13C-glucose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2024-11-15",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-10-26T11:27:03.629Z",
      "location_count": 2,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05736367"
    },
    {
      "nct_id": "NCT05498155",
      "title": "Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Neoadjuvant Olaparib monotherapy group",
          "type": "DRUG"
        },
        {
          "name": "Neoadjuvant combination therapy with olaparib plus durvalumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-11-07",
      "completion_date": "2025-09-16",
      "has_results": true,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-26T11:27:03.629Z",
      "location_count": 4,
      "location_summary": "Loveland, Colorado • Boston, Massachusetts • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Loveland",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05498155"
    },
    {
      "nct_id": "NCT00041067",
      "title": "S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "vinorelbine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 76,
      "start_date": "2002-09",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2013-06-06",
      "last_synced_at": "2026-10-26T11:27:03.629Z",
      "location_count": 145,
      "location_summary": "Mobile, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 89 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Castro Valley",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00041067"
    },
    {
      "nct_id": "NCT00877500",
      "title": "Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bilateral Breast Carcinoma",
        "HER2/Neu Negative",
        "Invasive Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Ixabepilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2009-03-30",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-26T11:27:03.629Z",
      "location_count": 3,
      "location_summary": "Oak Lawn, Illinois • Houston, Texas",
      "locations": [
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00877500"
    },
    {
      "nct_id": "NCT03691493",
      "title": "Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Estrogen Receptor Positive",
        "HER2/Neu Negative",
        "Metastatic Breast Carcinoma",
        "Metastatic Malignant Neoplasm in the Bone",
        "Progesterone Receptor Positive",
        "Prognostic Stage IV Breast Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2019-02-08",
      "completion_date": "2022-10-13",
      "has_results": true,
      "last_update_posted_date": "2025-02-17",
      "last_synced_at": "2026-10-26T11:27:03.629Z",
      "location_count": 10,
      "location_summary": "Atlanta, Georgia • Augusta, Georgia • Columbus, Georgia + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03691493"
    }
  ]
}